Abstract
Amyotrophic lateral sclerosis (ALS) is a difficult disease to study as it is mostly sporadic and rapidly progressive. Identification of genes causing familial ALS (FALS) has been instrumental in advancing our understanding of ALS pathogenesis, most notably with the use of mutant superoxide dismutase 1 (SOD1) models of disease. For 15 years SOD1 models have been the backbone of ALS research, but no effective treatments have been developed. However, recent advances have been made in the genetics of ALS with the identification of mutations in TAR DNA binding protein (TDP-43) and fused in sarcoma/translocated in liposarcoma (FUS), both of which have roles in RNA-processing and gene expression. Molecular links between ALS and frontotemporal dementia (FTD) are also suggested by linkage of ALS-FTD to chromosome 9. The study of the genetics of sporadic ALS (SALS) has been less fruitful, although this may change as we enter the era of resequencing. Further important clues as to the causes of ALS will come from the identification of other gene mutations that cause FALS, variants that increase susceptibility to SALS, and genetic factors that modify the ALS phenotype.
Keywords: Amyotrophic Lateral Sclerosis, Genetics, TDP-43, FUS
CNS & Neurological Disorders - Drug Targets
Title: Neuronal Death in Amyotrophic Lateral Sclerosis (ALS): What Can We Learn from Genetics?
Volume: 9 Issue: 3
Author(s): J. Sreedharan
Affiliation:
Keywords: Amyotrophic Lateral Sclerosis, Genetics, TDP-43, FUS
Abstract: Amyotrophic lateral sclerosis (ALS) is a difficult disease to study as it is mostly sporadic and rapidly progressive. Identification of genes causing familial ALS (FALS) has been instrumental in advancing our understanding of ALS pathogenesis, most notably with the use of mutant superoxide dismutase 1 (SOD1) models of disease. For 15 years SOD1 models have been the backbone of ALS research, but no effective treatments have been developed. However, recent advances have been made in the genetics of ALS with the identification of mutations in TAR DNA binding protein (TDP-43) and fused in sarcoma/translocated in liposarcoma (FUS), both of which have roles in RNA-processing and gene expression. Molecular links between ALS and frontotemporal dementia (FTD) are also suggested by linkage of ALS-FTD to chromosome 9. The study of the genetics of sporadic ALS (SALS) has been less fruitful, although this may change as we enter the era of resequencing. Further important clues as to the causes of ALS will come from the identification of other gene mutations that cause FALS, variants that increase susceptibility to SALS, and genetic factors that modify the ALS phenotype.
Export Options
About this article
Cite this article as:
Sreedharan J., Neuronal Death in Amyotrophic Lateral Sclerosis (ALS): What Can We Learn from Genetics?, CNS & Neurological Disorders - Drug Targets 2010; 9 (3) . https://dx.doi.org/10.2174/187152710791292558
DOI https://dx.doi.org/10.2174/187152710791292558 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Studies of p53 Tumor Suppression Activity in Mouse Models
Current Genomics PEGylation of Proteins and Liposomes: a Powerful and Flexible Strategy to Improve the Drug Delivery
Current Drug Metabolism Suicide Gene Therapy Mediated by the Herpes Simplex Virus Thymidine Kinase Gene / Ganciclovir System: Fifteen Years of Application
Current Gene Therapy The Role of C-Reactive Protein in Atherosclerotic Cardiovascular Disease: An Overview
Current Vascular Pharmacology The Antagonists of Endothelin Receptors: Results and Perspectives
Current Pharmaceutical Analysis Hsp90 Inhibitor Geldanamycin and Its Derivatives as Novel Cancer Chemotherapeutic Agents
Current Pharmaceutical Design Anti-tumoral Properties of Endogenous Angiogenesis Inhibitors: A Case for Continued TIMP-2 Preclinical Development
Current Angiogenesis (Discontinued) Lymphatic Targeting of Nanosystems for Anticancer Drug Therapy
Current Pharmaceutical Design Inhibition of Highly Pathogenic Avian H5N1 Influenza Virus Replication by NanoRNA Oligonucleotides
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry mRNA as a Versatile Tool for Exogenous Protein Expression
Current Gene Therapy Deregulation of the Akt Pathway in Human Cancer
Current Cancer Drug Targets Cytokine/Antibody Complexes: An Emerging Class of Immunostimulants
Current Pharmaceutical Design Protease Inhibitors in the Clinic
Medicinal Chemistry Reprogramming Cancer Cells in Endocrine-Related Tumors: Open Issues
Current Medicinal Chemistry Etiologic Aspects of Pagets Disease of Bone
Current Rheumatology Reviews Peptide-Receptor Ligands and Multivalent Approach
Anti-Cancer Agents in Medicinal Chemistry Docking Prediction for Luteolin Inhibiting TNF-α and NF-κB Pathway
Letters in Drug Design & Discovery Therapeutic Effects of Progesterone in Animal Models of Neurological Disorders
CNS & Neurological Disorders - Drug Targets Targeting RANK/RANKL in the Treatment of Solid Tumours and Myeloma
Current Pharmaceutical Design Structure of the Epidermal Growth Factor Receptor Gene and Intron Recombination in Human Gliomas
Current Genomics